RESUMEN
INTRODUCTION: Heart failure (HF) is one of the leading causes of morbidity and mortality worldwide. This study aimed to assess the impact of sex on sociodemographic, clinical, and laboratory parameters in patients with HF who were included in the Colombian Heart Failure Registry (RECOLFACA). METHODS: This was a cross-sectional analytical research. All 2528 patients included in RECOLFACA were analysed. The Mann-Whitney U test was used to compare median values as well as first and third quartiles (Q1-Q3). The age-related trend of NT-proBNP levels for both men and women groups was statistically evaluated. RESULTS: The study included 2528 patients with HF (1072 women and 1456 men). The echocardiographic evidence showed that men presented reduced left ventricular ejection fraction (LVEF) (79.63 vs. 69.75%, respectively; p < 0.001) more often than women, which had a significantly higher proportion of preserved LVEF (20.46 vs.11.24%, respectively; p < 0.001). Women displayed a higher value of systolic blood pressure (p < 0.001) and heart rate (p = 0.014) compared to men. Haemoglobin, creatinine, and sodium levels were significantly higher in men. Men had a considerably lower glomerular filtration rate value, with the median reaching a G3a value for chronic renal failure. According to age, the levels of NT-proBNP in each sex increased equivalently with age. CONCLUSION: Sex differences presented in this study are comparable to those discovered in other nations. However, certain variations show that these sex differences may differ by geographical area, which should encourage further investigations to describe them.
RESUMEN
Background: The value of Sodium-glucose cotransporter-2 inhibitors (SGLT-2 inhibitor) therapy in individuals with heart failure with preserved EF (HFpEF) was unknown until the EMPEROR-Preserved trial. We aimed to assess the proportion of patients with HFpEF that are eligible for empagliflozin therapy within the Colombian Heart Failure Registry (RECOLFACA). Methods: RECOLFACA enrolled adult patients with a HF diagnosis during 2017-2019 from 60 medical centers in Colombia. Criteria of the EMPEROR-Preserved Trial were used to recruit participants. The main outcome was individual eligibility with N-terminal pro-B-type natriuretic peptide (NT-proBNP) criteria, while the secondary outcome was eligibility without NT-proBNP data. Results: RECOLFACA had 799 patients with HFpEF (mean age70.7 ± 13.5; 50.7 % males). According to the major selection criteria of the EMPEROR Preserved Trial, 73.7 % patients would be eligible for empagliflozin therapy initiation when considering the NT-proBNP threshold. The NT-proBNP threshold represented the main determinant of ineligibility in patients with this biomarker measure (13.6 %; n = 16). In patients without NT-proBNP data, the main reasons for exclusion were the diagnosis of symptomatic hypotension or a systolic blood pressure below 100 mmHg (7.5 %), having an eGFR < 20 ml/min/1.73 m2 (4.3 %), and haemoglobin < 9 g/dl (3.1 %). Excluding NT-proBNP criteria increased empagliflozin eligibility to 80.6 %. Conclusion: Most patients with HFpEF from RECOLFACA are potential candidates for empagliflozin therapy initiation according to the EMPEROR-Preserved trial criteria. These findings favor the utilization of SGLT-2 inhibitor medications in daily medical practice, which may further decrease morbidity and mortality in HF patients, regardless of their EF classification.
RESUMEN
Objetivo. Evaluar el riesgo cardiovascular global y determinar la prevalencia del síndrome metabólico y los factores de riesgo cardiovascular en trabajadores del Hospital Universitario Ramón González Valencia (HURGV).Diseño. Estudio de corte transversal.Lugar. Hospital universitario.Población. Cuatrocientos catorce trabajadores del HURGV.Mediciones. Se realizó una encuesta sobre datos demográficos, antecedentes personales y familiares de riesgo cardiovascular; se midieron el peso, la talla, el perímetro de cintura y cadera y la presión arterial. Se determinó en sangre la glucemia en ayuno y el perfil lipídico. Se hizo un electrocardiograma y se calculó el riesgo cardiovascular a diez años mediante las tablas de Framingham y los criterios de la ILIB (International Lipid Boureau), la prevalencia de síndrome metabólico y factores de riesgo cardiovascular aplicando criterios del NCEP-ATP III (National Cholesterol Education Program - Adult Treatment Panel III) y la ILIB latinoamericana.Resultados. El promedio de edad fue 44.3 años, la mayoría mujeres eran 79.2 porciento; la población estudiada fue: 47.3 porciento auxiliares de enfermería; 6.3 porciento médicos y 9.4 porciento enfermeras; la prevalencia de hipertensión fue 54 porciento, obesidad central 40.3 porciento, sobrepeso 46.4 porciento, y obesidad 21 porciento; sedentarismo en 82.4 porciento, dislipidemia 24 porciento, tabaquismo 10.4 porciento; intolerancia a la glucosa 4.6 porciento y diabetes 1.6 porciento. El riesgo cardiovascular global a diez años fue 2.2 porciento (5.2 porciento hombres y 1.4 porciento mujeres). Según ILIB -Latinoamérica 17.3 porciento de la población está en riesgo intermedio para enfermedad coronaria y 3.3 porciento en riesgo alto, mientras que según el ATP III 1.9 porciento está en riesgo intermedio. El síndrome metabólico tuvo una prevalencia de 17.3 porciento (ILIB) y 13.2 porciento (ATP III). La población con mayores factores de riesgo y peores índices metabólicos correspondió ...